Guselkumab for Crohn's after ustekinumab
Part of Digestive system clinical trials.
This study looks at whether guselkumab, a different biologic medicine, can help people with Crohn's disease who have already tried ustekinumab but it didn't work well or caused side effects. It aims to see if switching to guselkumab is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have had Crohn's disease for at least 3 months.
- Your Crohn's disease is moderate to severe (scored between 220 and 450 on a symptom scale).
- You have previously been treated with at least one standard dose of ustekinumab, and it either didn't work initially, stopped working over time, or caused side effects that made you stop.
- You are willing and able to follow all study visits and procedures.
- You have never taken any other anti-IL-23p19 medicine (like guselkumab) before.
- No active gut infection, blocked bowel without surgery, short bowel syndrome, stoma, or recent abdominal abscess (within 8 weeks).
- No history of cancer (except certain skin cancers), active tuberculosis, or severe opportunistic infections.
- You are not pregnant, breastfeeding, or planning to get pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications—guselkumab and a JAK inhibitor—for people with inflammatory bowel disease that hasn't responded to other treatments. The goal is to see if this combination is safe and effective for patients with hard-to-control Crohn's disease or ulcerative colitis.
This study compares two medicines, Guselkumab and Ustekinumab, for people with Crohn's disease that causes narrowing (strictures) in the bowel. It aims to find which works better to improve symptoms and avoid the need for more procedures.
This study tracks how well a medication called guselkumab works for people with moderate to severe Crohn's disease who have had surgery to remove part of their intestines. Researchers want to see if this treatment helps prevent the disease from coming back.
This trial tests whether switching from the drug ustekinumab to another drug called guselkumab can help people with active inflammatory bowel disease (IBD) who didn't get enough benefit from ustekinumab. It focuses on people with Crohn's disease or ulcerative colitis who still have signs of inflammation in their gut.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study tests a new treatment for people with Crohn's disease who have lost response to ustekinumab (Stelara). It aims to see if a different dosing or additional treatment can help regain control of symptoms.
Hear when a new Inflamatory Bowel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.